Authors: Sarah Gierahn Nielsen, med. student & Hanne Melgaard Nielsen, MD
Breast cancer is comprised of different entities with well defined pathological features thus making accurate grouping of breast cancers into clinically relevant subtypes of extreme importance.
Immunohistochemistry markers such as estrogen (ER) -, progesteron (PR) – and HER 2 receptor status along with other prognostic factors are used for stratifying patients and choosing the optimal treatment.
- Dai, Xiaofeng et al. “Breast cancer intrinsic subtype classification, clinical use and future trends.” American journal of cancer research vol. 5,10 2929-43. 15 Sep. 2015